We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Advanced Biological Releases First Commercial CE-IVD Registered COVID-19 rRT-PCR Assay Also Validated for Saliva

By LabMedica International staff writers
Posted on 08 Jul 2020
Print article
Image: qRT-PCR Workflow (Photo courtesy of Advanced Biological Laboratories)
Image: qRT-PCR Workflow (Photo courtesy of Advanced Biological Laboratories)
Advanced Biological Laboratories (ABL Luxembourg) has announced the CE-IVD marking of its UltraGene Combo2Screen SARS-CoV-2 qPCR assay.

The UltraGene Combo2Screen SARS-CoV-2 qPCR assay is the first qPCR detection kit now validated with SARS-CoV-2 RNA extracted from nasopharyngeal swabs and saliva. The collection of saliva samples is not invasive and allows easier and broader population testing and screening. This optimization consisting in using saliva specimen as an input material for the SARS CoV-2 RNA extraction and qPCR detection, rather than traditional nasopharyngeal swabs, helps in improving the workflow, costs and convenience of the test together with the comfort of the patients. It allows targeting of asymptomatic patients, increasing acceptance of patients for testing and reducing workload and risk of infection for healthcare professionals performing nasopharyngeal or oropharyngeal collections. Patients collect saliva samples under the supervision of healthcare professionals under a simpler and painless collection protocol.

The UltraGene Combo2Screen CE-IVD assay targets two highly conserved regions of the SARS-CoV-2 genome (Nucleocapsid (N) and Envelop (E) genes) in a multiplex format which includes an internal control. The test remains one of the most sensitive and easy to use assays from the market (~200 cp/mL), either with naso-oropharyngeal or saliva samples. It is compatible with most of the automated or manual RNA extraction methods, as well as with most of the qPCR instruments.

“We are proud to enhance our COVID-19 line of solutions. Converting the assay into a non-invasive fluid saliva collection workflow should significantly help increasing the number of people being tested and ease the access to diagnostics to fragile population such as children or elderly patients and to asymptomatic patients” said Dr. Chalom Sayada, CEO of ABL. “Proactive saliva collection strategy at schools and business places shall be foreseen to monitor prospectively SARS-CoV-2 infection”

Related Links:
Advanced Biological Laboratories

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more